IL6 and metabolic dysfunction-associated steatohepatitis: Using anti-IL6 as a therapeutic target would require the proper optimization of the dose and administration due to the lack of any direct evidence of using anti-IL6 as a therapy in MASH models, although studies in related conditions suggest potential benefits [41,42].